Fri, Feb 27, 2015, 4:31 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • siestacottage siestacottage Jun 12, 2014 9:24 AM Flag

    news - June 12,2014

    Denver, CO, 06/12/2014 (Stocksntrade) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. This drug is a mix of VGX-3100, , INO’s lead active-immunotherapy product, & 12 (IL-12), its proprietary immune-activator expressing interleukin, VGX-3100 is now being evaluated in the randomized Phase-II efficacy-trial for treatment of the high-grade cervical dysplasia.

    Very Effective Response

    In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study. The CD8+ T cells indicated functional ability to effectively kill the target cells that display the E6 & E7 antigens. In the preclinical animal-models, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s HPV immunotherapy demonstrated 100 percent protection against the HPV E6 & E7-expressing tumors & prevented/ delayed growth of those tumors. This proprietary IL-12 immune activator- INO-9012 had earlier indicated that it could enhance antigen-specific CD4+ & CD8+ T-cell immune responses to INO’s PENNVAX® HIV-DNA vaccine in its clinical trial.

    The Nest Phases

    Inclusion of the DNA-based immune-activator in INO-3112 is specifically designed to increase generation of the HPV-specific CD8+ T cells for treatment of the HPV-related cancer. In the open-label study, that is named HPV-005, upto 20 adults suffering from HPV-positive head & neck squamous cell carcinoma will be treated with the company’s INO-3112. They will be followed for safety, immune & the clinical responses. In 1 segment part of this study, upto 10 patients will be treated with the INO-3112 before & after resection of the tumor. In the 2nd pa Less

 
INO
7.07+0.04(+0.64%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.